(Q44648851)

English

A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1 reference

based on heuristic

inferred from title

0 references

author name string

Mohammad Ebrahim Parsanezhad

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Saeed Alborzi

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Mahnaz Pakniat

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Ernst Heinrich Schmidt

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Fertility and Sterility

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

80

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1151-1155

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Complications of assisted reproductive techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Elevated concentrations of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Repeated aspiration of ovarian follicles and early corpus luteum cysts in an in-vitro fertilization programme reduces the risk of ovarian hyperstimulation syndrome in high responders

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Complications of ovulation induction

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

The use of ketoconazole as an inhibitor of steroid production

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Ketoconazole use in the treatment of ovarian hyperandrogenism

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Low dose ketoconazole is an effective and a relatively safe alternative in the treatment of hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901177-4

7 January 2021

Identifiers

10.1016/S0015-0282(03)01177-4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44648851&oldid=2098849999"